Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib

A large number of EGFR mutant non‐small cell lung cancer patients primordially benefit from first‐line treatment with first‐generation EGFR‐tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. However, multiple acquired resistance mechanisms have been described that limit the clinical...

Full description

Bibliographic Details
Main Authors: Kejing Tang, Neng Jiang, Yukun Kuang, Qiong He, Shuhua Li, Jiping Luo, Wenting Jiang, Yangshan Chen, Yu Sun, Lili Chen, Yanyang Chen, Junfeng Zhu, Yongmei Cui, Han Wan, Zunfu Ke
Format: Article
Language:English
Published: Wiley 2019-02-01
Series:Thoracic Cancer
Subjects:
EGFR
mutation
NSCLC
osimertinib
SCLC
Online Access:https://doi.org/10.1111/1759-7714.12927

Internet

https://doi.org/10.1111/1759-7714.12927

Similar Items